M&A Momentum in Q2 2026: HSR Early Termination, Cross-Border Energy Deals, and the AI Acquisition Wave
Mergers & Acquisitions

M&A Momentum in Q2 2026: HSR Early Termination, Cross-Border Energy Deals, and the AI Acquisition Wave

April 2026 M&A activity — from RB Global’s HSR early termination to Ecopetrol’s Brazilian energy acquisition — signals accelerating deal velocity alongside rising cross-border and AI-driven complexity. Decision-makers must integrate regulatory strategy, technical due diligence, and post-merger integration planning from the earliest stages of any transaction.

M&A Activity Accelerates in April 2026: Healthcare Tender Offers, Energy Consolidation, and What European Deal-Makers Must Watch
Mergers & Acquisitions

M&A Activity Accelerates in April 2026: Healthcare Tender Offers, Energy Consolidation, and What European Deal-Makers Must Watch

A concentrated burst of M&A activity in late April 2026 — spanning pharmaceutical tender offers, energy portfolio acquisitions, and mid-market technology consolidation — offers European and cross-border deal teams a timely strategic reference point. Regulatory sequencing, integration discipline, and sector-specific due diligence are the defining variables separating value creation from value erosion in the current market.

Cross-Border M&A in 2025: What the QXO–TopBuild $17B Deal and April's Wave of Transactions Signal for Global Deal-Makers
Mergers & Acquisitions

Cross-Border M&A in 2025: What the QXO–TopBuild $17B Deal and April’s Wave of Transactions Signal for Global Deal-Makers

April 2025’s M&A wave — led by QXO’s $17 billion TopBuild acquisition and a series of cross-border transactions — signals a market defined by strategic conviction, earnings discipline, and regulatory complexity. CFOs and M&A Directors must prioritise accretion structuring, parallel regulatory workstreams, and integration planning from day one.

Cross-Border M&A Accelerates in April 2026: What the UCB–Neurona and Badger Meter–UDlive Deals Signal for Corporate Dealmakers
Mergers & Acquisitions

Cross-Border M&A Accelerates in April 2026: What the UCB–Neurona and Badger Meter–UDlive Deals Signal for Corporate Dealmakers

April 2026 has seen a surge in cross-border M&A activity, with UCB’s acquisition of Neurona Therapeutics and Badger Meter’s $100M UDlive deal signalling a structural shift in how European and US strategic acquirers are deploying capital. Decision-makers must now treat due diligence rigour and post-merger integration planning as core competitive capabilities.